Minoru Takemoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2266472/publications.pdf

Version: 2024-02-01

68 1,411 16 35
papers citations h-index g-index

70 70 70 1871 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Rothmundâ€Thomson syndrome investigated by two nationwide surveys in Japan. Pediatrics International, 2022, 64, .	0.5	2
2	A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency. Experimental Hematology, 2022, 109, 11-17.	0.4	6
3	Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases. Journal of Medical Genetics, 2022, 59, 1087-1094.	3.2	14
4	Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with typeÂ2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIMEâ€V study). Journal of Diabetes Investigation, 2021, 12, 200-206.	2.4	14
5	Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment. Geriatrics and Gerontology International, 2021, 21, 160-162.	1.5	5
6	Management guideline for <scp>W</scp> erner syndrome 2020. 4. <scp>O</scp> steoporosis associated with <scp>W</scp> erner syndrome. Geriatrics and Gerontology International, 2021, 21, 146-149.	1.5	6
7	Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. Journal of Diabetes Investigation, 2021, 12, 454-458.	2.4	3
8	Management guideline for Werner syndrome 2020 8. Calcification in tendons associated with Werner syndrome. Geriatrics and Gerontology International, 2021, 21, 163-165.	1.5	5
9	Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. Geriatrics and Gerontology International, 2021, 21, 133-138.	1.5	4
10	Management guideline for <scp>Werner</scp> syndrome 2020. 3. Diabetes associated with <scp>Werner</scp> syndrome. Geriatrics and Gerontology International, 2021, 21, 142-145.	1.5	8
11	Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome. Geriatrics and Gerontology International, 2021, 21, 139-141.	1.5	5
12	Management guideline for <scp>W</scp> erner syndrome 2020. <scp>5</scp> . <scp>I</scp> nfection associated with <scp>W</scp> erner syndrome. Geriatrics and Gerontology International, 2021, 21, 150-152.	1.5	3
13	Preface to Management guideline for <scp>Werner</scp> syndrome 2020. Geriatrics and Gerontology International, 2021, 21, 131-132.	1.5	5
14	Management guideline for W erner syndrome 2020. 6. Skin ulcers associated with W erner syndrome: Prevention and nonâ€surgical and surgical treatment. Geriatrics and Gerontology International, 2021, 21, 153-159.	1.5	10
15	Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study. Diabetes Therapy, 2021, 12, 183-196.	2,5	17
16	A novel podocyte protein, R3h domain containing-like, inhibits TGF-β-induced p38 MAPK and regulates the structure of podocytes and glomerular basement membrane. Journal of Molecular Medicine, 2021, 99, 859-876.	3.9	3
17	Effects of Sodium Glucose Co-TransporterÂ2 Inhibitors in TypeÂ1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial. Diabetes Therapy, 2021, 12, 1415-1427.	2.5	6
18	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	5 . 5	13

#	Article	IF	CITATIONS
19	Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Scientific Reports, 2021, 11, 13450.	3.3	14
20	Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer. Frontiers in Oncology, 2021, 11, 708039.	2.8	14
21	Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. Asia Pacific Journal of Clinical Nutrition, 2021, 30, 424-435.	0.4	3
22	A Case of Hashimoto's Thyroiditis with Multiple Drug Resistance and High Expression of Efflux Transporters. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 399-406.	3.6	3
23	Serum antiâ€LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	3.9	16
24	Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon, 2020, 6, e04661.	3.2	16
25	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. Aging, 2020, 12, 24940-24956.	3.1	20
26	Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. International Journal of Molecular Medicine, 2020, 46, 1274-1288.	4.0	11
27	R3hdml regulates satellite cell proliferation and differentiation. EMBO Reports, 2019, 20, e47957.	4.5	9
28	Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, openâ€label, blindedâ€endpoint, randomized controlled study (PRIMEâ€V study). Diabetes, Obesity and Metabolism, 2019, 21, 1990-1995.	4.4	28
29	Dulaglutideâ€related bullous pemphigoid in a patient with type 2 diabetes: A case report. Geriatrics and Gerontology International, 2019, 19, 1289-1290.	1.5	6
30	Characteristic Clinical Features of Werner Syndrome with a Novel Compound Heterozygous WRN Mutation c.1720+1G>A Plus c.3139-1G>C. Internal Medicine, 2019, 58, 1033-1036.	0.7	1
31	Investigatorâ€initiated clinical study of a functional peptide, SRâ€0379, for limb ulcers of patients with Werner syndrome as a pilot study. Geriatrics and Gerontology International, 2019, 19, 1118-1123.	1.5	6
32	Diagnosis and Pathogenesis of Progeroid Syndromes. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 124-130.	0.0	0
33	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial. Npj Aging and Mechanisms of Disease, 2018, 4, 2.	4.5	8
34	Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2018, 9, 69-74.	2.4	25
35	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	1.8	38
36	Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack. Oncotarget, 2018, 9, 8836-8848.	1.8	18

#	Article	IF	CITATIONS
37	Transcription Factor 21 Is Required for Branching Morphogenesis and Regulates the Gdnf-Axis in Kidney Development. Journal of the American Society of Nephrology: JASN, 2018, 29, 2795-2808.	6.1	23
38	Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1082-1087.	1.9	30
39	Immune-mediated acquired lecithin-cholesterol acyltransferase deficiency: A case report and literature review. Journal of Clinical Lipidology, 2018, 12, 888-897.e2.	1.5	10
40	Biallelic <i>WRN</i> Mutations in Newly Identified Japanese Werner Syndrome Patients. Molecular Syndromology, 2018, 9, 214-218.	0.8	5
41	Generation of Endothelial and Smooth Muscle Cells from Werner Syndrome-Specific Induced Pluripotent Stem Cells. Juntendo Medical Journal, 2018, 64, 207-215.	0.1	0
42	Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2017, 126, 138-143.	2.8	5
43	Recent Trends in <i>WRN</i> Gene Mutation Patterns in Individuals with Werner Syndrome. Journal of the American Geriatrics Society, 2017, 65, 1853-1856.	2.6	13
44	Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). BMJ Open, 2017, 7, e015766.	1.9	6
45	Femoral osteoporosis is more common than lumbar osteoporosis in patients with Werner syndrome. Geriatrics and Gerontology International, 2017, 17, 854-856.	1.5	6
46	<i>WRN</i> Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects. Human Mutation, 2017, 38, 7-15.	2.5	79
47	Werner syndrome: a model for sarcopenia due to accelerated aging. Aging, 2017, 9, 1738-1744.	3.1	14
48	II. Pitfalls Pertaining to Management of Dyslipidemia in Daily Medical Practice. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 690-695.	0.0	0
49	Improved Glycemic Control and Vascular Function and Reduction of Abdominal Fat Accumulation with Liraglutide in a Case of Werner Syndrome with Diabetes Mellitus. Journal of the American Geriatrics Society, 2016, 64, 687-688.	2.6	6
50	Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus. Journal of Circulating Biomarkers, 2016, 5, 8.	1.3	12
51	Efficacy and safety of the dipeptidyl peptidasea€4 inhibitor sitagliptin compared with alphaa€glucosidase inhibitor in Japanese patients with typeÂ2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptinâ€1): A multicenter, randomized, openâ€label, nonâ€inferiority trial. Journal of Diabetes Investigation, 2015, 6,	2.4	18
52	Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus. Journal of the American Geriatrics Society, 2015, 63, 1271-1273.	2.6	16
53	Pituitary Adenylate Cyclase-Activating Polypeptide Protects Glomerular Podocytes from Inflammatory Injuries. Journal of Diabetes Research, 2015, 2015, 1-10.	2.3	18
54	Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. Journal of Diabetes Investigation, 2015, 6, 3-15.	2.4	161

#	Article	IF	CITATIONS
55	Pioglitazone Improves Fat Tissue Distribution and Hyperglycemia in a Case of Cockayne Syndrome With Diabetes. Diabetes Care, 2015, 38, e76-e76.	8.6	4
56	Helicobacter cinaedi infection in patients with diabetes: a case report. SpringerPlus, 2015, 4, 72.	1.2	6
57	Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals. International Journal of Cardiology, 2014, 177, 860-866.	1.7	1
58	Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey. Geriatrics and Gerontology International, 2013, 13, 475-481.	1.5	104
59	Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrome With Diabetes. Diabetes Care, 2013, 36, e119-e119.	8.6	11
60	Sitagliptin Successfully Ameliorates Glycemic Control in Werner Syndrome With Diabetes. Diabetes Care, 2012, 35, e83-e83.	8.6	10
61	Incidence and Characteristics of Metabolic Disorders and Vascular Complications in Individuals with <scp>W</scp> erner Syndrome in <scp>J</scp> apan. Journal of the American Geriatrics Society, 2012, 60, 997-998.	2.6	19
62	The roles of transforming growth factor- \hat{l}^2 and Smad3 signaling in adipocyte differentiation and obesity. Biochemical and Biophysical Research Communications, 2011, 407, 68-73.	2.1	89
63	Clinical Outcome and Mechanism of Soft Tissue Calcification in Werner Syndrome. Rejuvenation Research, 2008, 11, 809-819.	1.8	19
64	Large-scale identification of genes implicated in kidney glomerulus development and function. EMBO Journal, 2006, 25, 1160-1174.	7.8	196
65	NKâ€104, a 3â€hydroxyâ€3â€methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. British Journal of Pharmacology, 2001, 133, 83-88.	5.4	25
66	Enhanced Expression of Osteopontin in Human Diabetic Artery and Analysis of Its Functional Role in Accelerated Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 624-628.	2.4	108
67	Enhanced Expression of Osteopontin by High Glucose: Involvement of Osteopontin in Diabetic Macroangiopathy ^a . Annals of the New York Academy of Sciences, 2000, 902, 357-363.	3.8	30
68	Predictive model and risk engine web application for surgical site infection risk in perioperative patients with type 2 diabetes. Diabetology International, 0, , .	1.4	0